A groundbreaking study published in The Lancet has revealed that obesity significantly amplifies the risk of severe infections necessitating hospitalization or resulting in death. Drawing upon data from over half a million individuals, researchers have established that people living with obesity face a 70% higher likelihood of encountering serious infections compared to those of a healthy weight. The study breaks new ground by demonstrating that this elevated risk extends across a wide spectrum of infectious diseases beyond the well-documented impact seen during the COVID-19 pandemic.
The extensive observational study cohort comprised more than 540,000 adults, combining population data from Finland and the UK. Participants’ body mass indices (BMIs) were assessed initially, with follow-up periods averaging 13 to 14 years. This long-term monitoring enabled scientists to track the incidence of severe infectious diseases, defined as infections leading to hospital admissions or death. The findings consistently show a direct correlation between higher BMI and increased vulnerability to infections such as influenza, pneumonia, gastroenteritis, respiratory infections, and urinary tract infections.
Crucially, the risk did not plateau but rather escalated in tandem with increasing BMI. Individuals with severe obesity—defined as a BMI equal to or exceeding 40 kg/m²—were shown to experience a tripling in infection risk compared to those maintaining a BMI within the healthy range of 18.5 to 24.9 kg/m². To contextualize, UK Biobank participants with a healthy BMI had an annual risk of severe infection of approximately 1.1%, whereas those with obesity faced a risk of 1.8% annually, underlining the tangible impact on public health.
Delving into specific infection types, the study confirmed that obesity increases susceptibility not only to respiratory infections like COVID-19 and pneumonia but also to gastrointestinal infections and urinary tract infections. Interestingly, however, the data indicated no statistically significant increase in severe outcomes related to infections such as HIV or tuberculosis among obese individuals, suggesting that the immunological impairment linked to obesity may interact variably with different pathogens.
Globally, the implications of this research are staggering. By integrating infection mortality figures from the Global Burden of Diseases Study with obesity prevalence data, researchers estimate that approximately 10.8% of infectious disease deaths worldwide in 2023—amounting to some 600,000 fatalities—were attributable to obesity. This proportion varies markedly by country; for instance, obesity accounted for roughly one in four infectious disease deaths in the United States and one in six in the United Kingdom, highlighting the disproportionate burden in high-income nations with higher obesity rates.
The mechanistic underpinnings of this phenomenon likely involve obesity’s detrimental effects on the immune system. Adiposity is known to provoke chronic inflammation and impair immune cell function, which may compromise the body’s ability to mount effective responses against invading viruses, bacteria, and other pathogens. Moreover, the metabolic dysregulation characteristic of obesity, including insulin resistance and altered cytokine profiles, may exacerbate immune dysfunction, predisposing affected individuals to more severe infectious courses.
These findings have profound ramifications for public health and clinical practice. They emphasize the urgent need for comprehensive strategies that address obesity not only to mitigate chronic diseases like diabetes and cardiovascular conditions but also to curtail the rising toll of infectious diseases. Policy measures fostering access to affordable healthy foods, promoting physical activity, and supporting weight loss interventions must be prioritized. Additionally, healthcare providers should recognize the increased infectious risk in patients with obesity and ensure timely and appropriate immunization coverage to reduce preventable complications.
Researchers also spotlight the promise of emerging pharmacological interventions such as GLP-1 receptor agonists, which have demonstrated benefits for weight reduction and cardiovascular health. Preliminary evidence suggests these agents may also confer protection against severe infections by ameliorating obesity-associated immune impairments. Nonetheless, further research is needed to confirm these mechanisms and explore therapeutic avenues that could simultaneously address obesity and infection susceptibility.
While the study’s strengths include its extensive cohorts and long follow-up periods, limitations must be acknowledged. The observational nature precludes definitive causal inferences, and the cohorts from Finland and the UK may not perfectly represent global populations. Additionally, data from lower-resource settings may be less robust, necessitating cautious interpretation of global extrapolations. Future work should strive for broader population representation and mechanistic elucidation.
Professor Mika Kivimäki from University College London, who led the research, stresses the need to understand the broad biological pathways linking obesity to infectious disease risk. Given the anticipated global increase in obesity prevalence, the consequent rise in severe infections could pose a formidable challenge to healthcare systems worldwide. Addressing obesity thus emerges as a critical lever to improve resilience against infectious threats.
In sum, this landmark study extends our comprehension of obesity’s impact by illuminating its role as a substantial risk factor for severe infectious diseases beyond the scope of respiratory viruses alone. The findings underscore a pressing global health imperative to integrate obesity mitigation into infectious disease prevention frameworks and reinforce the vital importance of maintaining healthy body weight as a shield against severe infections.
Subject of Research: People
Article Title: Adult obesity and risk of severe infections: a multicohort study with global burden estimates
News Publication Date: 9-Feb-2026
Web References:
DOI link
References:
- Galli M, Benenati S, Laudani C, et al. Cardiovasculareffectsand tolerability of GLP-1 Receptor agonists: a systematic review and meta-analysis of 99,599 patients. J Am CollCardiol2025; 86: 1805–19.
- Global Burden of Diseases Study (details in the original paper).
Keywords: Obesity, Infectious diseases, Immunology, Epidemiology, Public health, BMI, Hospitalization, Mortality, Weight-loss drugs, Global health
